Immundnz develops and applies bioanalytical methods for use in pharmacokinetic and toxicokinetic studies of drug molecules in preclinical research. Available techniques are mass spectrometry (LC-MS) and immunoassays (ELISA). We also employ these techniques for biomarker quantification and validation studies.
We offer a unique mass spectrometry based assay, pAMS. This is a novel ultra sensitive assay which is up to a factor 1.000 more sensitive than conventional techniques like ELISA and LC-MS and can be applied in toxicokinetic, pharmacokinetic, microdose and ADME studies in non- and pre-clinical drug research and development. pAMS is highly suitabled for studying the pharmacokinetic properties of (modified) innovative medicines, like peptide and protein drugs. It enables bioanalytical studies in which limited sample volumes are available. Due to its high sensitivity, pAMS opens up the way for bioanalysis of highly potent compounds and compounds with low bioavailability and short half-life.